Editing Factor VII (section)

== Medical uses ==

[[Recombinant factor VIIa]], marketed under the trade names ''AryoSeven'' and ''NovoSeven'', is used for people with [[hemophilia]] (with [[Factor VIII]] or [[Factor IX|IX]] deficiency) who have developed antibodies against replacement coagulation factor.

It has also been used in the setting of uncontrollable hemorrhage,<ref>{{cite journal | vauthors = Roberts HR, Monroe DM, White GC | title = The use of recombinant factor VIIa in the treatment of bleeding disorders | journal = Blood | volume = 104 | issue = 13 | pages = 3858–3864 | date = December 2004 | pmid = 15328151 | doi = 10.1182/blood-2004-06-2223 | doi-access = free }}</ref><ref>{{Cite web |url=https://www.mcdonaldworley.com/xarelto-lawsuit.php |title=Uncontrolled Bleeding and Injury Lawsuit Claims |access-date=2015-08-26 |archive-url=https://web.archive.org/web/20160616163010/https://www.mcdonaldworley.com/xarelto-lawsuit.php |archive-date=2016-06-16 |url-status=dead }}</ref> but its role in this setting is controversial with insufficient evidence to support its use outside of clinical trials.<ref name=Cochrane2012>{{cite journal | vauthors = Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C | title = Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia | journal = The Cochrane Database of Systematic Reviews | volume = 3 | issue = 3 | pages = CD005011 | date = March 2012 | pmid = 22419303 | doi = 10.1002/14651858.CD005011.pub4 | hdl-access = free | hdl = 10871/13808 }}</ref> The first report of its use in hemorrhage was in an [[Israel]]i soldier with uncontrollable bleeding in 1999.<ref>{{cite journal | vauthors = Kenet G, Walden R, Eldad A, Martinowitz U | title = Treatment of traumatic bleeding with recombinant factor VIIa | journal = Lancet | volume = 354 | issue = 9193 | pages = 1879 | date = November 1999 | pmid = 10584732 | doi = 10.1016/S0140-6736(99)05155-7 | s2cid = 23159895 }}</ref> Risks of its use include an increase in arterial thrombosis.<ref name=Cochrane2012/> However, animal studies have not shown complications as seen in humans, in fact same of the studies show a better prognosis. In the military settings it is used as an off label intervention in complications related to disseminated intravascular coagulation related haemorrhage caused by penetrating trauma.<ref>{{cite journal | vauthors = Hodgetts TJ, Kirkman E, Mahoney PF, Russell R, Thomas R, Midwinter M | title = UK defence medical services guidance for the use of recombinant factor VIIa (rFVIIa) in the deployed military setting | journal = Journal of the Royal Army Medical Corps | volume = 153 | issue = 4 | pages = 307–309 | date = December 2007 | pmid = 18619169 | doi = 10.1136/jramc-153-04-18 | s2cid = 10776054 }}</ref>

Recombinant human factor VII while initially looking promising in [[intracerebral hemorrhage]] failed to show benefit following further study and this is no longer recommended.<ref>{{cite journal | vauthors = Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T | display-authors = 6 | title = Recombinant activated factor VII for acute intracerebral hemorrhage | journal = The New England Journal of Medicine | volume = 352 | issue = 8 | pages = 777–785 | date = February 2005 | pmid = 15728810 | doi = 10.1056/NEJMoa042991 | author1-link = Stephan A. Mayer | doi-access = free }}</ref><ref>{{cite journal | vauthors = Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T | display-authors = 6 | title = Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage | journal = The New England Journal of Medicine | volume = 358 | issue = 20 | pages = 2127–2137 | date = May 2008 | pmid = 18480205 | doi = 10.1056/NEJMoa0707534 | hdl-access = free | hdl = 10067/688040151162165141 }}</ref>